Agios Pharmaceuticals Inc (AGIO) Jumps 5.24% on January 12

Equities Staff |

Agios Pharmaceuticals Inc (AGIO) was among the biggest gainers on the Russell 2000 for Tuesday January 12 as the stock popped 5.24% to $49.91, representing a gain of $2.485 per share. Some 883,496 shares traded hands on 8,222 trades, compared with an average daily volume of 653,988 shares out of a total float of 37.64 million. The stock opened at $48.14 and traded with an intraday range of $55.02 to $47.02.

After today's gains, Agios Pharmaceuticals Inc reached a market cap of $1.88 billion. Agios Pharmaceuticals Inc has had a trading range between $138.85 and $45.12 over the last year, and it had a 50-day SMA of $62.55 and a 200-day SMA of $89.33.

Agios Pharmaceuticals Inc is engaged in the development of medicines to treat cancer metabolism and inborn errors of metabolism, which are a subset of orphan genetic metabolic diseases.

Agios Pharmaceuticals Inc is based out of Cambridge, MA and has some 96 employees. Its CEO is David P. Schenkein.

For a complete fundamental analysis analysis of Agios Pharmaceuticals Inc, check out’s Stock Valuation Analysis report for AGIO. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Propanc Health Group Corp

Propanc Health Group Corp is an early stage healthcare company. It is engaged in developing new cancer treatments for patients, suffering from pancreatic and colorectal cancer.

Private Markets


Pinterest is a visual discovery and planning tool. Users ("Pinners") use the site and apps to get ideas for their future, such as recipes, places to travel, and products to…

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…